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Hepatic Hepcidin Gene Expression in Dogs with a Congenital
Portosystemic Shunt
P.E. Frowde, A.G. Gow, C.A. Burton, R. Powell, V.J. Lipscomb, A.K. House, R.J. Mellanby, and
M.S. Tivers
Background: Microcytic anemia is common in dogs with a congenital portosystemic shunt (cPSS) and typically resolves
after surgical attenuation of the anomalous vessel. However, the pathophysiology of the microcytic anemia remains poorly
understood. Hepcidin has been a key role in controlling iron transport in both humans and animals and in mediating ane-
mia of inflammatory disease in humans. The role of hepcidin in the development of microcytic anemia in dogs with a cPSS
has not been examined.
Hypothesis: To determine whether hepatic hepcidin mRNA expression decreases, while red blood cell count (RBC) and
mean corpuscular volume (MCV) increase in dogs after surgical attenuation of a cPSS.
Animals: Eighteen client-owned dogs with confirmed cPSS undergoing surgical attenuation.
Method: Prospective study. Red blood cell count (RBC) and mean corpuscular volume (MCV), together with hepatic
gene expression of hepcidin, were measured in dogs before and after partial attenuation of a cPSS.
Results: There was a significant increase in both RBC (median pre 6.17 9 1012/L, median post 7.08 9 1012/L,
P < .001) and MCV (median pre 61.5fl, median post 65.5fl, P = .006) after partial surgical attenuation of the cPSS.
Despite the increase in both measured red blood cell parameters, hepatic gene expression of hepcidin remained unchanged.
Conclusions and Clinical Importance: This study found no evidence that dysregulated production of hepcidin was asso-
ciated with anemia in dogs with a cPSS.
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Anemia is commonly reported in dogs with a con-genital portosystemic shunt (cPSS) and has been
associated with abnormalities in iron metabolism.1
However, the precise pathogenesis of cPSS-associated
anemia remains unclear. Anemia has been documented
in both spontaneous1,2 and experimentally induced PSS3
and is often microcytic, which has prompted investiga-
tions into iron status of dogs with a cPSS. Previous stud-
ies have revealed a high incidence of hypoferremia in
dogs with a cPSS, ranging from 56 to 70%.1,2 Hypofer-
remia does not appear to be associated with absolute
iron deficiency, as evaluation of other markers of iron
status do not support this conclusion. For example,
total iron binding capacity (TIBC) has been found to be
normal or reduced and transferrin saturation is highly
variable in dogs with cPSS, whereas more reliable mark-
ers of nonheme iron stores (serum ferritin concentration
and hepatic stainable iron) are normal or increased in
many individuals.1,2,4 In addition, liver iron content
(analyzed quantitatively) doubled in dogs after experi-
mentally induced PSS.3 Iron parameters have been
shown to return to normal after partial shunt attenua-
tion, supporting a causal relationship between abnor-
malities and cPSS.1 It is therefore suspected that
hypoferremia in dogs with cPSS is caused by abnormal
iron sequestration or transport rather than true iron
deficiency.1,5 In summary, although these studies have
indicated that iron metabolism is dysregulated in dogs
with a cPSS, they have not clearly defined the pathogen-
esis of microcytic anemia in this disease.
Hepcidin, a hormone synthesized predominantly by
hepatocytes, controls iron transport by binding and
inhibiting (via degradation) the iron-export protein
ferroportin.6 Hepcidin expression is increased in both
anemia of chronic disease and iron overload, and
decreased with regenerative anemia/erythropoiesis,
hypoxia, some forms of hereditary hemochromatosis,
and experimentally induced iron deficiency.6 Increased
hepcidin expression, induced by sustained up-regulation
of IL-6 during chronic inflammation, has been pro-
posed as the main mediator of anemia of chronic
disease because of iron-restricted erythropoiesis.7,8 This
observation is particularly relevant to dogs with a cPSS
because IL-6 concentrations are increased in dogs with
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a cPSS compared to healthy control dogs (Kilpatrick S,
Gow AG, Foale RD, Tappin SW, Carruthers H, Reed
N, Yool DA, Woods S, Marques AI, Jalan R, Mellanby
RJ, personal communication). Therefore, IL-6-induced
up-regulation of hepcidin is a plausible explanation for
the frequent occurrence of microcytic anemia which is
commonly observed in dogs with a cPSS.
The hypothesis of this prospective study was that
hepatic hepcidin mRNA expression would decrease,
while red blood cell count (RBC) and mean corpuscular
volume (MCV) would increase in dogs with a cPSS after
partial surgical attenuation of the anomalous vessel. This
hypothesis was examined by measuring RBC and MCV,
together with hepatic gene expression, before and after
partial surgical attenuation of the anomalous vessel.
Dogs undergoing surgery for cPSS were considered
for inclusion into the study. Dogs were treated by par-
tial or complete suture attenuation determined by sub-
jective and objective intraoperative assessments of
portal hypertension. Dogs treated with partial attenua-
tion had a follow-up surgery approximately 3 months
later for complete attenuation. Dogs that had partial
attenuation and follow-up surgery were eligible for
inclusion in the study.
Blood samples were collected before each surgery by
jugular venipuncture for hematology which included
red blood cell count and mean corpuscular volume
assessment. A single liver biopsy specimen was col-
lected during the initial and follow-up shunt surgery
for routine histopathology in formalin and for qPCR
in RNAlater. RNAlater samples were stored at 80°C.
Hematocrit, erythrocyte number (RBC), and mean
corpuscular volume (MCV) were determined in EDTA
anticoagulated blood with an automated hematology
analyzer (impedence counter and laser flow cytometer).a
RNA was extracted from approximately 20–30 mg
of each hepatic biopsy sample with a Mammalian
Total RNA Miniprep Kit.b The tissue was homoge-
nized in 500-ll Lysis Solution with a Mixer Mill.c An
in-solution DNase digestion was performed with the
Ambion TURBO DNA-free Kitd to remove any con-
taminating DNA. RNA quality and quantity was
assessed by microfluidic capillary electrophoresis with
a Bioanalyzer.e Two separate cDNA were synthesized
from each RNA sample using a mixture of random
hexamer and oligo (dT)15 primers and reverse trans-
criptase enzyme.f Where possible the amount of RNA
template for cDNA synthesis was standardized at
1 lg. The cDNA was diluted to a final volume of
100 lL with nuclease-free water and was stored at
20°C before further use.
Quantitative polymerase chain reaction (qPCR) was
used to measure the relative expression of hepcidin
mRNA in hepatic tissue from cPSS dogs at first and
second surgery. Previously published canine gene spe-
cific primers for hepcidin6 and 4 liver-specific reference
genes9, hydroxymethyl-bilane synthase (HMBS), ribo-
somal protein L13a (RPL13A), ribosomal protein L32
(RPL32), and ribosomal protein S18 (RPS18), were
used (Table 1).
For quantification, each liver sample had 2 cDNA
samples analyzed in duplicate. Reactions were carried
out in 25-lL volumes with a Real-Time PCR Detection
System thermocycler.g Each reaction consisted of 1-lL
cDNA as the template with Immobuffer (19 concentra-
tion), Hi-Spec Additive (19 concentration), dNTP (final
concentration 1 mM), magnesium chloride (final con-
centration 2.5 mM for genes of interest, 4.5 mM for ref-
erence genes), 1 unit Immolase DNA polymerase,h and
EvaGreen dyef (0.069 diluted 1:4 with nuclease free
water). Samples were incubated at 95 °C for 10 min fol-
lowed by 40 cycles of denaturation at 94 °C for 30 sec-
onds, annealing at 55°C for 30 seconds, and elongation
at 72°C for 10 seconds. A primer-dimer melting temper-
ature of 80°C for 1 second was programmed before flu-
orescence readings were taken at the end of each cycle.
A melting curve analysis from 65 to 95°C with a plate
read every 0.5°C was performed at the end of 40 cycles.
Initial qPCR analysis was performed,i followed by
analysis of raw real-time data.j Relative gene expression
was quantified as previously described.10 Quantification
cycle (Cq) values were corrected using the calculated
efficiencies for each primer set. Normalization of each
sample Cq for hepcidin was performed relative to the
geometric normalization of the 4 reference genes. The
relative expression of hepcidin mRNA in each cDNA
sample was calculated using the normalized Cq of each
sample relative to the average Cq of all of the samples.
Statistical analysis was performed by a statistical
software package.k Median and range were reported,
and data compared with the Wilcoxon Signed Rank
test. Significance was set at the 5% level (P = .05).
Table 1. Primers used in quantitative polymerase chain reaction.
Gene Primer Sequences
PCR Amplicon
Length (Base Pairs)
Genbank Accession
Number
Primer Sequence
Reference
Hepcidin Forward: GGCCAGTGTCTCAGTCCTTC
Reverse: GTTTTACAGCAGCCACAGCA
168 AY590589 Fry et al6
HMBS Forward: TCACCATCGGAGCCATCT
Reverse: GTTCCCACCACGCTCTTCT
112 XM546491 Peters et al9
RPL13A Forward: GCCGGAAGGTTGTAGTCGT
Reverse: GGAGGAAGGCCAGGTAATTC
87 AJ388525 Peters et al9
RPL32 Forward: TGGTTACAGGAGCAACAAGAAA
Reverse: GCACATCAGCAGCACTTCA
100 XM848016 Peters et al9
RPS18 Forward: TGCTCATGTGGTATTGAGGAA
Reverse: TCTTATACTGGCGTGGATTCTG
116 XM532106 Peters et al9
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This study was approved by the Royal Veterinary
College Ethics Committee and written informed con-
sent was gained before recruitment of all cases.
Results
Eighteen dogs with a cPSS met the inclusion criteria.
A variety of ages (median age 154 days, range 96–
1769), breeds, and sex were represented (Table S1).
There was a significant increase in RBC count after
partial attenuation of the shunting vessel (median pre
6.17 9 1012/L [range 4.31–7.58], median post 7.08 9
1012/L [range 5.49–8.54], P < .001). There was also a
significant increase in MCV after partial shunt attenua-
tion (median pre 61.5fl [range 51.4–67.7], median post
65.5fl [range 54.9–72.3], P = .006). These changes were
in keeping with findings of previous studies.1
The median relative mRNA expression of hepcidin
at first surgery was 2.51 (0.04–15.01) and at second
surgery the median relative mRNA expression of
hepcidin was 2.25 (0.01–8.87). This difference was not
statistically significant.
The central finding of this study was that hepatic
hepcidin mRNA expression showed no significant
change after partial surgical ligation of the cPSS. The
lack of change in hepatic gene expression of hepcidin
cannot be explained by a lack of change in the RBC or
MCV as both parameters significantly increased after
partial attenuation of the shunting vessel. We were
therefore unable to demonstrate a role for altered hepa-
tic hepcidin mRNA expression in the pathogenesis of
microcytic anemia in dogs with cPSS. However, future
studies with more dogs may have a greater power to
detect a difference in hepcidin expression postsurgery.
It would have been useful to compare hepatic hepcidin
mRNA expression in cPSS dogs (before attenuation)
with age-matched control dogs (without hepatic dis-
ease) to further support the conclusion that hepcidin
expression is unaltered in dogs with a cPSS. However,
such controls were not available to us because of ethi-
cal and logistical limitations beyond our control.
We have also not ruled out the possibility that hepatic
hepcidin up-regulation is present at the level of protein
translation rather than mRNA expression, or even that
extrahepatic sites of hepcidin expression exist and become
more important in dogs with hepatic dysfunction. On the
other hand, nonhepcidinmediators (including other acute
phase proteins/cytokines implicated in the pathophysiol-
ogy of anemia of inflammatory disease in dogs) could be
involved andmaywarrant further investigation.
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Additional Supporting Information may be found in
the online version of this article:
Table S1. Individual data (signalment, time between
surgeries, haematological and qPCR data pre and post
partial shunt attenuation surgery).
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